Conference call today at 9:00 am ETQ4 2025 revenues of $112M, +46% vs. Q4 2024 Furoscix® Q4 2025 net sales of $23M, +91% vs. Q4 2024 Afrezza® Q4 2025 net sales of $23M, +25% vs. Q4 2024 2025 full year revenues of $349M, +22% vs. 2024Successfully completed the acquisition of scPharmaceuticals Inc. (scPharma)Program updates: Afrezza pediatric indication PDUFA date May 29, 2026Furoscix ReadyFlow™ Autoinjector PDUFA date July 26, 2026 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) ...

Core Insights - MannKind Corporation has successfully completed the acquisition of scPharmaceuticals Inc, which is expected to diversify and accelerate its revenue growth, particularly through the innovative therapy FUROSCIX® for edema related to chronic heart failure and chronic kidney disease [1][2] - The acquisition enhances MannKind's commercial and medical capabilities by integrating scPharmaceuticals' experienced team, positioning the company for further growth in cardiometabolic care [2] - MannKind's annualized revenue run rate exceeds $370 million based on Q2 2025 results, supported by its commercial assets including Afrezza®, FUROSCIX®, and V-Go® [1] Acquisition Details - The acquisition was structured as a tender offer at a price of $5.35 per share in cash, plus a non-tradable contingent value right (CVR) for potential milestone payments, totaling up to $6.35 per share [3] - Approximately 73.47% of scPharmaceuticals' outstanding shares were tendered, allowing the transaction to proceed, with scPharmaceuticals becoming a wholly owned subsidiary of MannKind [4] - Following the acquisition, scPharmaceuticals' common stock ceased trading on Nasdaq [5] Strategic Fit and Future Growth - The strategic alignment between MannKind and scPharmaceuticals creates significant growth opportunities by combining MannKind's endocrinology expertise with scPharmaceuticals' cardiovascular capabilities [2] - MannKind aims to expand FUROSCIX's market reach among nephrologists and cardiologists, enhancing its position in chronic heart failure treatment [2] - The company has a late-stage pipeline that includes Inhaled Clofazimine and nintedanib DPI, which supports long-term value creation [2]

Group 1 - Halper Sadeh LLC is investigating Vital Energy, Inc. for potential violations related to its sale to Crescent Energy Company, where shareholders will receive 1.9062 shares of Crescent Class A common stock for each share of Vital common stock [1] - scPharmaceuticals Inc. is being investigated for its sale to MannKind Corporation, offering shareholders a cash payment of $5.35 per share plus a non-tradable contingent value right (CVR) worth up to $1.00 per CVR upon achieving specific milestones [2] - The firm may seek increased consideration for shareholders and additional disclosures regarding the proposed transactions [3] Group 2 - Shareholders are encouraged to contact Halper Sadeh LLC to discuss their legal rights and options at no charge [4] - Halper Sadeh LLC represents investors globally who have experienced securities fraud and corporate misconduct, recovering millions for defrauded investors [4]

Core Insights - MannKind Corporation has agreed to acquire scPharmaceuticals Inc. for a deal value of up to approximately $360 million, or $5.35 per share, marking a strategic expansion into cardiorenal medicine [1] - The acquisition is supported by MannKind's recent $500 million strategic financing agreement with Blackstone [1] Company Overview - ScPharmaceuticals markets Furoscix, an FDA-approved on-body infuser for treating fluid overload in adult patients with chronic heart failure and chronic kidney disease, with a total addressable market opportunity exceeding $10 billion in the U.S. [2] - For the six months ended June 30, scPharmaceuticals reported net sales of $27.8 million, reflecting a 96% year-over-year increase [2] Product Development - The Furoscix ReadyFlow Autoinjector is expected to submit a supplemental New Drug Application in Q3 2025, aiming to reduce treatment time from five hours to less than 10 seconds [3] Strategic Goals - MannKind's CEO highlighted that the acquisition expands patient-centered brands and demonstrates the company's commitment to innovative therapies for cardiometabolic and orphan lung diseases, with expectations for double-digit growth over the next decade [4] - The combined company will own Afrezza, Furoscix, and V-Go, with an annualized run rate of over $370 million based on second-quarter 2025 earnings [4] Market Reaction - Following the acquisition announcement, scPharmaceuticals' stock rose by 15.36% to $5.59, while MannKind's stock decreased by 4.50% to $3.93 [5] Pipeline Advancements - MannKind is advancing a late-stage pipeline that includes inhaled Clofazimine (MNKD-101) for nontuberculous mycobacterial lung disease and Nintedanib DPI (MNKD-201), which is expected to initiate a phase 2 clinical trial for idiopathic pulmonary fibrosis by the end of 2025 [6]

Company Performance - Cytek Biosciences, Inc. reported quarterly earnings of $0.01 per share, exceeding the Zacks Consensus Estimate of a loss of $0.02 per share, and showing improvement from a loss of $0.08 per share a year ago, resulting in an earnings surprise of +150.00% [1] - The company posted revenues of $45.6 million for the quarter ended June 2025, which was 3.3% below the Zacks Consensus Estimate and a decrease from $46.62 million in the same quarter last year [2] - Over the last four quarters, Cytek has surpassed consensus EPS estimates three times but has only topped revenue estimates once [2] Stock Performance - Cytek Biosciences shares have declined approximately 40.2% since the beginning of the year, contrasting with the S&P 500's gain of 7.1% [3] - The current Zacks Rank for Cytek is 4 (Sell), indicating expectations of underperformance in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is $0.02 on revenues of $52.78 million, while for the current fiscal year, it is projected at -$0.01 on revenues of $204.97 million [7] - The outlook for the Medical - Biomedical and Genetics industry, where Cytek operates, is currently in the bottom 42% of over 250 Zacks industries, suggesting potential challenges ahead [8]

Insmed (INSM) came out with a quarterly loss of $1.42 per share versus the Zacks Consensus Estimate of a loss of $1.36. This compares to loss of $1.06 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -4.41%. A quarter ago, it was expected that this biopharmaceutical developing inhaled treatments for patients battling rare lung diseases would post a loss of $1.15 per share when it actually produced a loss of $1.32, delivering a ...